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Role of Matriptase and Proteinase-Activated
Receptor-2 in Nonmelanoma Skin Cancer
Georgeta Bocheva1,7, Anke Rattenholl2,3,7, Cordula Kempkes2, Tobias Goerge2, Chen-Yong Lin4,
Michael R. D’Andrea5, Sonja Sta¨nder2 and Martin Steinhoff2,3,6
Matriptase (membrane-type serine proteinase) was reported to play a role in nonmelanoma skin cancer
progression. Moreover, it was shown to stimulate proteinase-activated receptor-2 (PAR2) in vitro. Hepatocyte
growth factor activator inhibitor-1 (HAI-1), the matriptase inhibitor, is an important regulator of enzyme activity.
Therefore, the aim of this study was to elucidate the putative role of matriptase, HAI-1, and PAR2 in normal
human skin, as well as in basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs). In normal human
epidermis, PAR2 colocalized with matriptase and HAI-1. Immunoreactivity of all proteins was found to be
diminished in BCCs. Likewise, PAR2 immunoreactivity was significantly decreased, whereas matriptase
immunoreactivity was enhanced with SCC progression. We could also show that matriptase was complexed
to HAI-1 in normal human skin, whereas in SCCs, the enzyme was present in an unassociated form. Both a
specific peptide agonist for PAR2 and the proteinase domain of matriptase were able to induce intracellular
calcium mobilization and inhibition of proliferation in cultured HaCaT keratinocytes. In conclusion, our results
suggest that PAR2 is a substrate for matriptase in human skin in vivo. Deregulation of these proteins delineates
SCC progression.
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INTRODUCTION
Matriptase is a trypsin-like proteinase that was first isolated
from human milk. It is well produced by all types of epithelia,
and was shown to be overexpressed in several carcinomas
with epithelial origin (Oberst et al., 2001). In human
epidermis, matriptase is mainly produced by keratinocytes
from the stratum granulosum and the first corneal layer. It is
moderatly expressed in the stratum spinosum and the stratum
basale (Oberst et al., 2003). It is an important enzyme within
the epidermis, allowing for the correct processing of
profilaggrin. Filaggrin aggregates keratin inside the keratino-
cytes and facilitates cornified envelope as well as lipid matrix
formation (List et al., 2003). Mice lacking matriptase die
shortly after birth due to fatal water loss. Moreover, hair
follicle growth is impaired (List et al., 2002).
Matriptase is translated as an inactive, single-chain
zymogen. Activation requires two sequential endoproteolytic
cleavages. Moreover, interaction with its cognate inhibitor,
hepatocyte growth factor activator inhibitor (HAI-1), is
important for the regulation of matriptase activity (Szabo
et al., 2007). HAI-1 is a Kunitz-type serine proteinase
inhibitor with a membrane anchor. There exists strong
evidence that the matriptase/HAI-1 ratio is dysreguated in
epithelial cancers: an increased matriptase/HAI-1 mRNA
ratio correlated with tumor progression in studies of color-
ectal and prostate cancer (Saleem et al., 2006; Vogel et al.,
2006). In addition, tumor as well as cancer cell extracts
contain both the matriptase–HAI-1 complex as well as free
matriptase protein, in contrast to normal epithelial cell
extracts (Oberst et al., 2001; Benaud et al., 2002). Moreover,
it was shown that matriptase-induced skin tumorigenesis was
repressed by coexpression of HAI-1 in a transgenic mouse
model (List et al., 2005). Indeed, matriptase expression is
regarded as a prognostic marker for esophageal squamous
cell, breast, renal, ovarian, prostate, and hepatocellular
carcinomas (Cheng et al., 2006; Sanders et al., 2006; Tsai
et al., 2006; Jin et al., 2006a, b, 2007).
Serine proteinases do not only act as enzymes that degrade
proteins, for example, of the extracellular matrix, or that are
involved in blood coagulation. They can also function as
signaling molecules that activate certain G protein-coupled
receptors, the proteinase-activated receptors (PARs) (Steinhoff
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et al., 2005). PARs exhibit seven transmembrane domains.
The activation mechanism involves specific cleavage of the
extracellular N terminus that exposes a tethered ligand
domain which is able to bind to the second extracellular
loop. This, in turn, causes activation of downstream signaling
events. In vitro, the receptors can also be stimulated without
proteolytic cleavage by certain activating peptides that mimic
the tethered ligand. To date, four PARs have been cloned
(PAR14). PAR2 can be activated by proteinases with trypsin-
like activity, including matriptase (Takeuchi et al., 2000). The
receptor is produced by many cell types present in the skin,
including fibroblasts, nerves, dendritic cells, endothelial
cells, mast cells, and leukocytes (Rattenholl and Steinhoff,
2008). In the epidermis, the receptor is well expressed by
suprabasal keratinocytes (Steinhoff et al., 1999), and recent
observations prove the importance of PAR2 for epidermal
barrier homeostasis (Hachem et al., 2006; Demerjian et al.,
2008). We could show that PAR2-deficient mice develop
significantly more chemically induced papillomas compared
with the wild-type controls (Rattenholl et al., 2007). Thus,
PAR2 may play a crucial growth-promoting role only in
certain tissues, whereas in the skin and possibly other
epithelia, it may exert a tumor-protective function.
Therefore, we localized the distribution of PAR2, matrip-
tase, and HAI-1 in normal skin as well as in basal and
squamous cell carcinomas (SCCs) of different stages, and
analyzed the protein levels in normal and tumor skin tissues.
Finally, the effect of matriptase on intracellular calcium
mobilization and proliferation was tested in a human
keratinocyte cell line (HaCaT).
RESULTS
Immunohistochemical analysis of matriptase, HAI-1, and
PAR2 in epidermal skin tumors
A total of 12 normal skin sections and 58 skin carcinomas—
19 basal cell carcinomas (BCCs), 39 SCCs of different
histological grades—were stained by immunohistochemistry
for either matriptase, HAI-1, or PAR2, using specific mono-
clonal and polyclonal antibodies, as described in Materials
and Methods.
Matriptase and HAI-1
In normal human skin, we found immunoreactivity for
matriptase and HAI-1 selectively in suprabasal keratinocytes
of the epidermis. Both proteins were located mainly
intracellularly, and immunoreactivity was most prominent
in the upper granular and first corneal layers (Figure 1a
and b). Immunohistochemical staining for matriptase and for
HAI-1 was observed in both the cytoplasm and the cell
membranes of normal and tumor keratinocytes.
Representative immunohistological pictures of matriptase
and HAI-1 in BCCs and SCCs are presented in Figure 2, and
the statistical evaluation is shown in Figure 3. In tumor cells,
both proteins were found intracellularly as well as on the cell
membrane. Although matriptase was reported to be upregu-
lated in several cancers, we were surprised to find a
significant downregulation of this enzyme in BCCs as
compared with normal skin. Both matriptase and HAI-1
were absent even in many of the BCCs examined. One
example is shown in Figure 2a and b (superficial BCC). In
contrast, we found a gradual upregulation of matriptase
immunoreactivity during SCC progression. These observa-
tions are in line with reports from other groups investigating
other cancers with epithelial origin (Cheng et al., 2006;
Sanders et al., 2006; Tsai et al., 2006; Jin et al., 2006a, b,
2007). Likewise, HAI-1 immunoreactivity increased with SCC
progression (Figure 3b).
Proteinase-activated-receptor 2
Proteinase-activated receptor-2 was reported to be a substrate
for matriptase. Thus, it was postulated that matriptase could
be involved in SCC progression through activation of this
receptor (List et al., 2006a). On the other hand, we could
show that in a mouse carcinogenesis model, PAR2 acts as a
tumor suppressor (Rattenholl et al., 2007). To further study
the role of PAR2 in human BCC and SCC progression in vivo,
we also perfomed immunohistochemical analysis of this
receptor in these tumors as compared with normal human
skin. The polyclonal antibody used for this study has been
successfully used by others for immunofluorescence in the
skin (Hachem et al., 2006).
In the epidermis of normal human skin, PAR2 was
moderately expressed in suprabasal layers, and immunor-
eactivity was mainly located intracellularly, indicating that
this receptor was stored in vesicles (Figures 1 and 3c) (Bohm
et al., 1996). Immunoreactivity was absent or weak in basal
keratinocytes. Double immunofluorescence staining of ma-
triptase/PAR2 and HAI-1/PAR2 in normal epidermis showed
that both the enzyme and the inhibitor were almost fully
Matriptase
HAI-1 PAR2 Merge
PAR2 Merge
Figure 1. Double immunofluorescence staining of normal human skin for
matriptase and HAI-1 with PAR2. All proteins were found in the spinous and
granular layers of the epidermis. Matriptase (a, left panel) and HAI-1 (b, left
panel) were localized also in the first corneal layer, where PAR2 was not
present (arrowheads). Immunoreactivity was found mainly intracellularly. The
perfect colocalization of matriptase and its inhibitor reflects the tight
regulation of matriptase activity during normal skin homeostasis. Likewise,
PAR2 was also nearly fully colocalized with the other proteins, suggesting that
matriptase might be an activator for PAR2 in normal human skin in vivo. The
dotted lines denote the position of the basement membrane. Bar¼ 50 mm.
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Figure 2. Immunoreactivity of matriptase, HAI-1, and PAR2 in nonmelanoma skin cancer tissues. Immunolabeling of matriptase and HAI-1 was absent and almost
absent from (a and b) superficial and (d and e) nodular BCCs, respectively. Mast cells showed strong immunoreactivity for HAI-1 (arrowheads). Likewise, PAR2
was not expressed by (c and f) both types of BCCs. (g–i) Immunoreactivity for matriptase, HAI-1, and PAR2 was also downregulated in SCCs in situ. In the tumor
tissue of this patient, PAR2 was preferably located on the cell surface, implying that the receptor was present but probably not activated. (j–l) Immunohistochemistry of
an initial SCC. In this tumor, both matriptase and HAI-1 were localized on the cell surface. Of note, PAR2 immunoreactivity had vanished from the leading edge
of the tumor cells invading the dermis. (m–o) Both matriptase and HAI-1 were strongly expressed in well-differentiated SCCs, whereas PAR2 was only present
in certain tumor cells, which might have retained a higher grade of differentiation. (p–r) Analysis of a moderate to poorly differentiated SCC. Note the strong
immunoreactivity for (p) matriptase and (q) HAI-1 within the invasive tumor cells of the deeper dermis. In contrast, immunoreactivity for PAR2 had nearly completely
vanished during tumor progression. Staining for PAR2 was totally absent from dedifferentiated, spindle-like tumor cells (arrowheads). Bar¼100mm.
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colocalized with PAR2. PAR2 immunoreactivity was absent
only from the first corneal layer, where both the other
proteins could be found (Figure 1, merged pictures).
In BCCs, PAR2 was significantly downregulated. We did
not even detect any immunoreactivity for PAR2 in all
superficial BCCs examined. Surprisingly, we did not find a
significant overall downregulation of PAR2 in SCCs in situ,
initial and well differentiated SCCs, as compared to normal
skin (Figure 3c), although the receptor was clearly down-
regulated in certain areas of the tumor. On the other hand, we
observed that the immunoreactivity for PAR2 was increased
in non-neoplastic epidermal cells surrounding the tumor
tissue as compared to normal human skin (Figure 2f).
However, we detected a significant downregulation of
PAR2 immunoreactivity with SCC progression (Figures 2r
and 3c). Interestingly, in well- and less differentiated SCCs,
PAR2 immunoreactivity was observed predominantly in
keratinized squamous cell components of the tumors.
Staining was absent from undifferentiated spindle-like tumor
cells (Figure 2o and r).
These results obtained by immunohistochemistry regard-
ing PAR2 were confirmed by semiquantitative reverse
transcription PCR, verifying specificity (Figure 3d). PAR2
was well expressed in normal skin and SCCs in situ.
Moreover, PAR2 expression was upregulated in tumor-
surrounding tissue. In BCCs and the initial SCC examined,
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Figure 3. Statistical analysis of matriptase, HAI-1, and PAR2 immunoreactivity. (a) Matriptase was significantly downregulated in both types of BCCs and in
SCCs in situ. With the degree of SCC dedifferentiation, an increase in matriptase immunoreactivity was observed. (b) Immunoreactivity for the matriptase
inhibitor HAI-1 was comparable to the distribution of matriptase. (c) PAR2 was totally absent from superficial BCCs, and immunoreactivity was negative to weak
in nodular BCCs. PAR2 immunoreactivity was also significantly diminished in moderate to poorly differentiated SCCs. (d) The results obtained for PAR2 by
immunohistochemistry were confirmed by semiquantitative PCR. Note that the expression of PAR2 was enhanced in healthy skin tissue surrounding an SCC.
Data are presented as box plots with minimum and maximum observations. Outliers are marked as black dots. Straight lines: medians; dotted lines: means.
A two-sided Mann–Whitney U-test was used for comparisons between groups. The numbers given represent n. *Pp0.05; **Pp0.01; ***Pp0.001.
www.jidonline.org 1819
G Bocheva et al.
Matriptase and PAR2 in Skin Tumors
PAR2 expression was clearly downregulated. The slight band
seen in the superficial BCC specimen was probably caused
by a ‘‘contamination’’ with tumor-surrounding normal tissue
during sample preparation, as we could not detect PAR2
immunoreactivity in all sections of these tumors. In addition,
we performed immunohistochemical stainings with selected
tumor sections using the polyclonal anti-PAR2 antibody B5.
This antibody has been successfully used for the expression
analysis of PAR2 in human melanomas (Massi et al., 2005).
This antibody yielded an identical staining pattern compared
with the other polyclonal antibody used in this study
(Figure S1).
Activation of matriptase in normal skin versus lesional skin
The presence of matriptase in normal skin as well as BCCs
and SCCs from representative patients was analyzed by
immunoblot analysis (Figure 4). With the monoclonal M32
antibody, two matriptase forms could be observed: one band
at 130 kDa and a double band at 85 kDa. The theoretical
molecular weight of the unprocessed matriptase precursor is
95 kDa. The proteinase undergoes N-terminal processing by
cleavage at Gly-149 within the SEA domain. Therefore, the
85 kDa double band could be the cleaved form of matriptase.
Interestingly, the levels of this 85 kDa band strongly increased
in the SCCs examined compared with normal skin and BCCs.
In normal human skin, the 130 kDa matriptase form
prevailed. Immunoblot analysis with the HAI-1 antibody
showed that this form was the proteinase–inhibitor complex
that did not dissociate during sample preparation. From
superficial BCCs, as expected, matriptase was almost
absent. We were able to detect some matriptase immunor-
eactivity in the nodular BCC sample that was probably due to
normal epidermis surrounding the tumor. In SCCs of different
stages, we found that the enzyme was mostly present in a
free form.
Matriptase induces intracellular calcium mobilization in and
inhibits proliferation of HaCaT keratinocytes
Activation of PAR2 was reported to inhibit proliferation of
human primary keratinocytes and HaCaT cells, a human
keratinocyte cell line, in vitro (Derian et al., 1997). It was also
observed that matriptase is able to activate PAR2 on
transfected Xenopus oocytes leading to intracellular calcium
release (Takeuchi et al., 2000). Thus, it can be assumed that
stimulation of HaCaT keratinocytes with matriptase should
lead to inhibition of proliferation. To address this issue, we
first tested whether stimulation of HaCaT cells with a
selective PAR2 activating peptide (AP-2) or the proteinase
would lead to an increase of the intracellular calcium
concentration. Indeed, the addition of AP-2 to HaCaT
keratinocytes induced a rapid calcium signal in these cells,
which was not observed upon addition of the reverse
sequence (RP-2, negative control; Figure 5a). Likewise,
HaCaT cells showed a strong fluorescence signal in the
calcium assay after supplementation with matriptase. As the
enzyme caused this physiological effect in HaCaT cells, we
next tested whether it should also be able to inhibit cell
MW
(kDa)
130
100
70
55
Matriptase HAI-1
Uncomplexed
matriptase
Matriptase–HAI-1
complex
No
rm
al 
sk
in
Ini
tia
l S
CC
SC
C 
in 
sit
u
No
du
lar
 B
CC
Su
pe
rfic
ial
 B
CC
No
rm
al 
sk
in
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matriptase was present. Immunoblot analysis using the HAI-1 antibody
showed this form to be the enzyme–inhibitor complex. Matriptase was also
found in SCCs of different stages. However, here the enzyme was present in
an uncomplexed 85 kDa form.
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Figure 5. Cellular responses to matriptase in HaCaT keratinocytes.
Both (a) a specific activating peptide for PAR2 (AP-2; 10
4
M) and (b)
matriptase proteinase domain (0.35 mgml1) induced a fast and strong
intracellular calcium mobilization in cultured HaCaT keratinocytes. (a) In
contrast, the scrambled control peptide (RP-2; 104 M) did not induce a
calcium signal. (c) Both AP-2 (104 M) and the matriptase proteinase domain
(0.35mgml1) significantly inhibited the proliferation of HaCaT cells to a
similar extent (47 and 35% inhibition, respectively). The data shown are the
results of three independent experiments. Data are presented as means
±SEM. Differences between data were tested by Student’s t-tests for unpaired
data. ***Pp0.001.
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proliferation. As expected, matriptase was able to signifi-
cantly inhibit proliferation of HaCaT cells to a comparable
degree as AP-2 (Figure 5c).
DISCUSSION
To our knowledge, this study is the first report investigating
the distribution of the serine proteinase matriptase and its
possible substrate, the PAR2 receptor, in human BCCs and
SCCs of the skin as well as a potential colocalization.
In a mouse model of chemically induced skin carcinogen-
esis, List et al. (2006b) showed that premalignant and
malignant epidermal keratinocytes showed increased
matriptase immunoreactivity. This is in line with our
observations: we also found a significant upregulation of
matriptase immunoreactivity with SCC progression. Surpris-
ingly, matriptase immunoreactivity was found to be signifi-
cantly downregulated in all BCCs examined. Immunoblot
analysis showed that in normal skin, matriptase was mainly
found to be complexed with HAI-1. In contrast, in SCCs, the
enzyme primarily was not bound to its inhibitor, indicating
that protease activity might be dysregulated.
Proteinase-activated receptor-2 is a putative substrate of
matriptase (Takeuchi et al., 2000), and both the receptor and
the proteinase were reported to play an important role in
epidermal barrier function. Whereas matriptase-deficient
mice die shortly after birth due to lethal water loss through
the skin, PAR2-null mice are vital. Yet they are prone to
increased formation of papillomas in a chemically induced
skin carcinogenesis model. We found that in PAR2-deficient
mice, keratinocyte proliferation was significantly enhanced
compared with the wild-type controls after single topical
treatment with the tumor promoter TPA (12-O-tetradecanoyl-
phorbol-13-acetate) (Rattenholl et al., 2007). We analyzed
the immunoreactivity of PAR2 in normal skin compared with
BCCs and SCCs. We found a moderate staining for PAR2 in
suprabasal keratinocytes, whereas basal keratinocytes did not
produce PAR2, as reported elsewhere (Steinhoff et al., 1999;
Hachem et al., 2006). PAR2 was also totally or nearly absent
from all BCCs, and it was significantly downregulated with
SCC progression. In addition, we performed immunofluores-
cence costaining experiments of matriptase and PAR2. In
normal human skin, both proteins were found to be totally
colocalized. Interestingly, both proteins were mainly loca-
lized intracellularly, indicating both to be mainly located in
intracellular stores. In SCCs, the receptor, if present, mostly
stained inside the tumor cells. In contrast, strong immuno-
fluorescence reactivity for matriptase was detectable both
inside the tumor cells as well as on the cell membrane.
Immunoreactivity on the cell surface might indicate that
enzyme activity was enhanced in these tumors, which
correlates with the results obtained by immunoblotting. BCCs
are thought to originate from keratinocytes of the hair
follicle, which express PAR2 to a comparable extent as
epidermal keratinocytes and with a similar distribution
pattern (Steinhoff et al., 1999). Of note, neither matriptase
nor HAI-1 expression was upregulated in BCCs, suggesting
that the proteinase does not play a significant role in BCC
tumor biology.
Furthermore, we could show in vitro that stimulation of
PAR2 on HaCaT keratinocytes with either a specific
PAR2-activating peptide or matriptase induced a transient
signal of intracellular calcium mobilization as well. We also
found a significant downregulation of HaCaT cell prolifera-
tion in serum-containing medium in the presence of either
PAR2-activating peptide or matriptase. This was not the case
for the negative control. This is in line with another report
that described a PAR2-mediated inhibition of keratinocyte
proliferation (Derian et al., 1997).
Taken together, both matriptase and PAR2 seem to play an
important role in normal epidermal homeostasis. Both
proteins were colocalized in keratinocytes, except in the first
corneal layer, where PAR2 could not be found but the
enzyme is ultimately necessary for the processing of
profilaggrin. After epidermal barrier disruption, PAR2 is
activated by serine proteinases, probably including matrip-
tase, thereby leading to a downregulation of lamellar body
secretion and accelerated keratinocyte terminal differentia-
tion, that is, cornification (Jeong et al., 2008). Other possible
roles of matriptase and PAR2 in normal keratinocyte home-
ostasis might be the regulation of keratinocyte proliferation.
Matriptase was reported to be a prognostic marker in several
epithelial cancers. Surprisingly, it does not seem to play a role
in BCC progression and invasion, although it might be
processed to a larger proportion in the surrounding epidermis
(Figure 4, lane 3). Nevertheless, both matriptase and PAR2
together are important markers for SCC progression: in
contrast to normal human skin, matriptase is essentially
not bound to its inhibitor in these tumors, and PAR2
immunoreactivity is significantly downregulated with SCC
progression.
MATERIALS AND METHODS
Antibodies
The primary antibody directed against human PAR2 was purchased
from Santa Cruz (CA; rabbit polyclonal antibody H99; dilution for
immunohistochemistry: 1:500). Anti-matriptase antibodies (mAb
clone S5 and M32) and anti-HAI-1 (mAb clone M19) were used
for immunohistochemistry in a concentration of 1 and 5 mgml1,
respectively (Oberst et al., 2001; Lee et al., 2005).
Patients
Permission for human studies was given by the Ethical Committee of
the University of Mu¨nster, Germany. The study was conducted
according to the Declaration of Helsinki principles. It included 10
superficial BCCs (8 males and 2 females, age 51–86 years, mean
66.8 years), 9 nodular BCCs (4 males and 5 females, age 48–98
years, mean 70.4 years), 8 SCCs in situ (type Bowen’s disease)
(5 males and 3 females, age 50–78 years, mean 68.7 years), 12 initial
SCCs (10 males and 2 females, age 42–87 years, mean 71.0 years),
10 well differentiated SCCs (5 males and 5 females, age 31–82 years,
mean 62.6 years), 9 moderate to poorly differentiated SCCs
(5 males and 4 females, age 64–90 years, mean 81.0 years). Normal
skin (n¼ 12) was obtained from postoperative material (4 males and
8 females, age 20–86 years, mean 59.2 years). Patients did not
receive topical medications within 2 weeks before obtaining
biopsies.
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Immunohistochemistry
Five- to six-micrometer paraffin sections were dewaxed, rehydrated,
and heated in a steamer (MultiGourmet plus FS20, Braun, Kronberg,
Germany) for 25minutes in 0.1 M ChemMate Target Retrieval
Solution (DakoCytomation, Glostrup, Denmark) in a plastic cuvette.
Sections were allowed to cool in this buffer for 20minutes.
Endogenous peroxidase activity was quenched with 100mM NaN3/
0.1 % (w/v) H2O2 in phosphate-buffered saline (PBS) for 20minutes
at RT. After washing with PBS, sections were blocked with 2% (w/v)
BSA in PBS for 25minutes at RT. Sections were incubated with first
antibodies diluted in 1% (w/v) BSA overnight at 4 1C in a humid
chamber. After rinsing with PBS, slides were incubated with second
antibodies for 1 hour at RT in a humid chamber (EnVisionþ System
Labelled Polymer-HRP, anti-rabbit or anti-mouse; Dako Cytoma-
tion). The immunoreactivity was detected with the Liquid DABþ
Substrate Chromogen System (Dako Cytomation). Nuclei were
counterstained with Hematoxylin QS (Vector Laboratories, Burlin-
game, CA) and mounted with Aquamount (BDH, Poole, UK).
Stainings were examined using a DM LB microscope (Leica, Solms,
Germany), equipped with an HV-C20M CCD camera (Hitachi,
Rodgau, Germany) and Diskus 4.20 software (Carl H. Hilgers,
Ko¨nigswinter, Germany). The staining of the sections was scored as
follows: (0) no cells positive, (1) 0–25% positive tumor cells (weak),
(2) 25–50% positive cells (moderate), (3) 50–75% positive cells,
(4) more than 75% positive tumor cells (strong).
Immunofluorescence microscopy
To examine a possible colocalization of matriptase or HAI-1 and
PAR2, we performed double immunofluorescence staining with
cryosections. Sections were incubated with the first primary Abs
overnight, and then after washes in PBS, with the second primary
anti-PAR2 antibody for 2.5 hours. Sections were washed with PBS
and incubated with fluorescence-conjugated secondary Abs for
1 hour (mixture of Texas red-labeled anti-mouse (1:40) and FITC-
labeled anti-rabbit (1:50) antibodies, DakoCytomation, Carpinteria,
CA). After washing again with PBS, slides were mounted with
Fluoromount-G (Southern Biotechnology Assoc., Birmingham, AL).
Sections were examined using an LSM 510 Meta confocal
microscope (Zeiss, Jena, Germany).
Tissue extraction
Frozen human normal skin, skin adjacent of a tumor, and skin
carcinoma specimens were ground in liquid nitrogen to a fine
powder using mortar and pestle. Next, whole RNA and protein were
isolated with Trizol (Invitrogen, Karlsruhe, Germany) according to
the manufacturer’s instructions.
Immunoblotting
Proteins were boiled in sample buffer (50mM Tris-HCl, pH 6.8; 2%
(w/v) SDS; 0.1% (w/v) bromophenol blue; 10% (v/v) glycerol; and
2.5% (v/v) 2-mercaptoethanol) for 5minutes, resolved by 10% (w/v)
SDS-PAGE, and transferred to a nitrocellulose membrane (Hybond
ECL, GE Healthcare Life Sciences, Freiburg, Germany). The
membrane was blocked for 30minutes with 5% (w/v) milk
powder (Sigma, St Louis, MO) in Tris-buffered saline with 0.05%
(v/v) Tween 20 (Sigma) and then incubated with primary anti-
matriptase Ab clone M32 or anti-HAI-1 Ab clone M19 in 1% (w/v)
milk powder in Tris-buffered saline overnight at 4 1C. After washes in
Tris-buffered saline, the membrane was incubated with peroxidase-
labeled anti-mouse secondary antibody (1:3,000; GE Healthcare Life
Sciences) in 2 % (w/v) milk powder in Tris-buffered saline for
1.5 hours. Immunoreactive polypeptides were visualized using the
ECL Plus Western Blotting Detection Kit (GE Healthcare Life
Sciences).
Semiquantitative reverse transcription PCR
A quantity of 1mg whole RNA was reverse-transcribed with
Superscript II reverse transcriptase according to the manufacturer’s
instructions (Invitrogen). Subsequent PCRs were carried out using the
GoTaq DNA polymerase from Promega (Mannheim, Germany). The
following primers were used. Forward h-PAR2: CCATCCAAGGAAC
CAATAG; reverse h-PAR2: CTGAGGCAGGTCATGAAG; forward
h-b-actin: AAGGAGAAGCTGTGCTACGTC; reverse h-b-actin: AAG
GAGAAGCTGTGCTACGTC. PCR conditions: PAR2—annealing
temperature 58 1C, 35 cycles; b-actin—annealing temperature
60 1C, 25 cycles. PCR products were resolved with a 2% (w/v)
agarose gel.
Cell culture
HaCaT keratinocytes were kindly provided by Dr Petra Boukamp,
German Cancer Center, Heidelberg, Germany. The cells were
cultured in RPMI 1640 medium supplemented with 10% (v/v)
fetal calf serum, 2mM L-glutamine, 100Uml1 penicillin, and
100mgml1 streptomycin (all from PAA Laboratories, Co¨lbe,
Germany). The PAR2-activating peptide AP-2 (SLIGKV-NH2) and
the reverse control peptide RP-2 (LSIGKV-NH2) were purchased
from Bachem (Weil am Rhein, Germany).
Proliferation assay
For proliferation assay, 150,000 cells per ml were cultured in
96-well-bottom plates in a final volume of 200 ml. Simultaneously,
1mCi per well [3H]thymidine (GE Healthcare Life Sciences)
was added for 48 hours and thymidine incorporation was
measured by liquid scintillation counting using the liquid
scintillation cocktail Betaplate Scint (Perkin Elmer, Waltham, MA)
and the scintillation counter 1450 Microbeta Plus (Wallac, Turku,
Finland).
Calcium mobilization assay
HaCaT cells were seeded on glass slides (Bellco Cover-Slips,
9 22mm, Electron Microscopy Sciences, Washington, PA) and
grown to confluency. Then the medium was changed and cells
were kept in the medium without fetal calf serum for 24 hours.
Next, coverslips were washed once with prewarmed Hank’s
Buffer containing 0.1% BSA and subsequently incubated
with 2.5 mM Fura 2AM (Invitrogen) for 30minutes at 37 1C.
Extracellular Fura 2AM was removed by rinsing in warm Hank’s
buffer and transferred into a UV cuvette. Fluorescence
measurements, corresponding to the elevations of cytosolic calcium,
were measured at 37 1C with a Spex Fluoromax 2 fluorescence
spectrofluorometer (Horiba Jobin Yvon, Munich, Germany) using
dual excitation at 340 and 380nm. Emission was recorded at
510 nm. The fluorescence ratio, which is proportional to the
intracellular [Ca2þ ]i concentration, was calculated. Measurements
were performed in triplicate with at least two independently grown
groups of cells.
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Statistical analysis
Immunohistochemical results are expressed as medians with range
for a series of experiments. Possible differences between groups were
determined using the two-sided Mann–Whitney U-test. Proliferation
assay data are presented as means±SEM. Differences between data
were tested by Student’s t-tests for unpaired data. A P of p0.05 was
considered statistically significant.
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